Contact Us
INNOGLY INNOGLY INNOGLY INNOGLY
Navigation
  • About us
    • COST Action
    • Network members
    • Scientific Outputs
      • Scientific Publications
      • Abstracts from Events
  • News
  • Events
  • Working Groups
    • Development and Cancer
    • Autophagy
    • Immunity
    • GAGs
  • STSM
    • STSM information
    • STSM proposal
    • STSM evaluation
    • Awarded STSMs
  • ITC Grants
  • Training Schools

Logged out

Lost Password?

News

Training School on the Conjugation of Glycans onto Nanomaterials
The COST action "INNOGLY" (Innovation with glycans: new frontiers from ...
Read More
Glycosaminoglycan Interaction Networks and Databases
The article GLYCOSAMINOGLYCAN INTERACTION NETWORKS AND DATABASES , by Sylvie Ricard Blum and ...
Read More
INNOGLY Annual Meeting 2022 (4-6 May Lugano)
4-6 May 2022, Lugano, Switzerland The Annual Meeting of the INNOGLY ...
Read More
Exploring the Multifaceted Roles of Glycosaminoglycans (GAGs): Special Issue Reprint
Read More
GlycosAminoGlycans: What remains to be solved?
  Scientific and Organizing Committee: Dragana Nikitovic & Serge Perez Topical organizing ...
Read More

Emerging glyco‐based strategies to steer immune responses

Abstract

Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell‐cell communications and in the regulation of immune responses. Through the interaction with glycan‐binding receptors glycans are able to affect the activation status of antigen presenting cells, leading to either induction of pro‐inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco‐chemists and glyco‐immunologists to develop glycan‐based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review we highlight emerging advances in this field, and in particular we discuss on how glycan‐modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen presenting cells, like dendritic cells. In addition, we address how glycan‐based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan‐based therapies, including chimeric antigen receptor (CAR)‐T cells to achieve targeting of tumor‐associated glycan‐specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity.

https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15830

March 25, 2021

Events

Training School on the Conjugation of Glycans onto Nanomaterials
The COST action "INNOGLY" (Innovation with glycans: new frontiers from ...
Read More
WORKSHOP “Neuroglycoproteins in Health and Disease” 24-25 March 2022 Alicante (Spain)
Read More
INNOGLY Annual Meeting 2022 (4-6 May Lugano)
4-6 May 2022, Lugano, Switzerland The Annual Meeting of the INNOGLY ...
Read More

Follow us on Twitter


Follow INNOGLY

Twitter Timeline

RT @FedeCompos: An overview on alternative/innovative methodologies for glycosidic bond formation in our latest review on @CarbohydrateRes…

RT @dr_inclan: I’ve remade this old animation to show the aqueous core of the liposome as the lipid bilayer disappears.
Using #geometrynode…

RT @bmmc_9: 📢It is our pleasure to announce that the Scientific Programme is now available online.
Follow the link for more details: https…

RT @GarozzoDomenico: Un viaggio nel fantastico mondo dei glicani | CNR. It was an amazing duet conference (in Italian) with @MolinaroTony o…

RT @IainWil92988866: Serge Perez @Glycopedia talks about hierarchies in starch structure – remarkable beauty at microscopic and molecular l…

POLICY STATEMENT:

Biomedicine and Molecular Biosciences Action CA18103 is funded by COST, which is supported by the EU Framework Programme Horizon 2020.

COST Action CA18103

© Copyright 2022. All Rights Reserved | Powered by innogly.eu | Designed by AWA
  • Imprint
  • /
  • Privacy policy
  • /
  • Cookie Policy (EU)
  • /
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Preferences
{title} {title} {title}